Theravance Biopharma, Inc. (TBPH) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
Last theravance biopharma, inc. - ordinary shares earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.theravance.com/investor-relations
Company Research
Source: Seeking Alpha
Company Participants Rick Winningham - CEO & Director Rhonda Farnum - Chief Business Officer and Senior VP of Commercial & Medical Affairs Aine Miller - Senior VP of Development & Head of Ireland Office Aziz Sawaf - Senior VP & CFO Conference Call Participants Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Julian Harrison - BTIG, LLC, Research Division Ellen Horste - TD Cowen, Research Division Presentation Operator Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma Third Quarter 2025 Conference Call. [Operator Instructions] Also, today's conference call is being recorded. And now I'd like to turn the call over to Rick Winningham, Chief Executive Officer. Please go ahead, sir. Rick Winningham CEO & Director Good afternoon, and welcome to Theravance Biopharma's Third Quarter 2025 Earnings Results Conference Call. On Slide 2, you'll find our forward-looking statements disclaimer, which covers cer
Show less
Read more
Impact Snapshot
Event Time:
TBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TBPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TBPH alerts
High impacting Theravance Biopharma, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
TBPH
News
- Theravance Biopharma (NASDAQ:TBPH) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.MarketBeat
- Theravance Biopharma (NASDAQ:TBPH) had its price target raised by analysts at BTIG Research from $25.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
- Theravance Biopharma (NASDAQ:TBPH) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TBPH&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 [Yahoo! Finance]Yahoo! Finance
- Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025PR Newswire
TBPH
Earnings
- 11/10/25 - Beat
TBPH
Sec Filings
- 12/3/25 - Form 144
- 12/1/25 - Form 4
- 11/26/25 - Form 144
- TBPH's page on the SEC website